Results 31 to 40 of about 1,097,021 (302)
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis +2 more
doaj +1 more source
Molecular Architecture of the DNA Replication Origin Activation Checkpoint [PDF]
Perturbation of DNA replication initiation arrests human cells in G1, pointing towards an origin activation checkpoint. We used RNAi against Cdc7 kinase to inhibit replication initiation and dissect this checkpoint in fibroblasts.
Claire Mulvey +13 more
core +1 more source
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo +22 more
core +1 more source
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher +7 more
doaj +1 more source
Ocular Neisseria gonorrhea in a patient on immune checkpoint inhibitors
Although immune checkpoint inhibitors have revolutionized the treatment of cancers, their role in the pathogenesis of chronic infections remains unclear.
Anuoluwapo Sopeyin +2 more
doaj +1 more source
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis [PDF]
Background and Objectives Rates of malignant melanoma are continuing to increase, and, until recently effective treatments were lacking. Since 2011, three immunotherapeutic agents, known as checkpoint inhibitors, have, however, been approved. This review
Saleh SN +5 more
core +1 more source
Research Progress of Immune Checkpoint Inhibitors in Colorectal Cancer
Tumor immunity is a new line of research for the treatment of patients with solid tumors, and negative regulators of the immune system called immune checkpoints play a key role in limiting antitumor immunologic responses.
ZHUANG Yuwen +3 more
doaj +1 more source
Checkpoint inhibitors in ovarian cancer: A review of preclinical data
Ovarian cancer is the deadliest gynecologic malignancy, and relapse after initial treatment is frequently fatal. Although ovarian cancer typically has an immunosuppressive tumor microenvironment, a strong intratumoral T cell presence is associated with ...
David W. Doo +2 more
doaj +1 more source
Determinants of Resistance to Checkpoint Inhibitors [PDF]
The development of immune checkpoint inhibitors (ICIs) has drastically altered the landscape of cancer treatment. Since approval of the first ICI for the treatment of advanced melanoma in 2011, several therapeutic agents have been Food and Drug Administration (FDA)-approved for multiple cancers, and hundreds of clinical trials are currently ongoing ...
Linda Tran, Dan Theodorescu
openaire +2 more sources
Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis.
John Apostolidis +4 more
doaj +1 more source

